Connexion
E-mail
Mot de passe
Afficher le mot de passe
Retenir
Mot de passe oublié ?
Devenir membre gratuitement
Inscription
Inscription
Devenir membre
Inscription gratuite
Devenir client
Découvrez nos services
Paramètres
Paramètres
Cotations dynamiques 
OFFON

OBSEVA SA

(OBSV)
  Rapport
SynthèseCotationsGraphiquesActualitésNotationsAgendaSociétéFinancesConsensusRévisionsDérivésFondsCommunauté 
SynthèseToute l'actualitéReco analystesAutres languesCommuniquésPublications officiellesActualités du secteur
Actualités dans d'autres langues sur OBSEVA SA
02/12ObsEva Announces Symposium and Presentation of Clinical Data on Oral GnRH Antagonist Li..
02/12ObsEva SA Announces Symposium and Presentation of Clinical Data on Oral GnRH Antagonist..
22/11ObsEva Shares Rise As FDA Accepts Linzagolix Application
22/11OBSEVA : Announces U.S. FDA Acceptance of New Drug Application for Linzagolix - Form 6-K
22/11AKTIEN SCHWEIZ : Kaum verändert zum Start in die Woche
22/11ObsEva Says FDA Accepts New Drug Application for Linzagolix
22/11Morning Briefing - Markt Schweiz
22/11Obseva kommt mit Linzagolix in den USA einen Schritt weiter
22/11Obseva's Uterine Fibroids Drug Accepted For Review by US FDA
22/11Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix
22/11Obseva SA Announces U.S. FDA Acceptance of New Drug Application for Linzagolix
22/11Obseva Announces Appointment of Stephanie Brown to its Board of Directors
22/11ObsEva SA Announces Board Changes
04/11AKTIEN SCHWEIZ SCHLUSS : SMI rettet kleines Plus
04/11INDEX TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Form 6-K
04/11AKTIEN SCHWEIZ : SMI setzt dank Big Pharma Aufwärtstrend fort
04/11AKTIEN SCHWEIZ ERÖFFNUNG : SMI setzt Anstieg fort - Big Pharma im Fokus
04/11ObsEva Books Q3 Profit, Operating Expenses Decline
04/11Biotechfirma Obseva mit Gewinn im dritten Quartal
04/11ObsEva Announces Third Quarter 2021 Financial Results and Business Update
04/11ObsEva SA Reports Earnings Results for the Third Quarter and Nine Months Ended Septembe..
01/11Morning Briefing - Markt Schweiz
01/11ObsEva CFO to Leave in January 2022
29/10ObsEva Announces Management Change - Form 6-K
29/10Obseva-Finanzchef tritt per Anfang 2022 zurück
29/10ObsEva CFO to Step Down
29/10ObsEva Announces Management Change
29/10Obseva Sa Announces Resignation of Current Chief Financial Officer David Renas, Effecti..
20/10Obseva präsentiert Studienresultate zu Linzagolix an Fachkongress
20/10OBSEVA : Presents Clinical Data on Oral GnRH Antagonist Linzagolix for the Treatment of Ut..
20/10ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix for the Treatment of U..
19/10OBSEVA : Announces Presentation of Clinical Data on Oral GnRH Antagonist Linzagolix at ASR..
13/10OBSEVA : Announces Relationship with Syneos Health to Commercialize Linzagolix - Form 6-K/..
13/10OBSEVA : Starts Partnership With Syneos Health For Drug Commercialization
13/10OBSEVA : Announces Relationship with Syneos Health to Commercialize Linzagolix - Form 6-K
13/10OBSEVA : Syneos Health Collaborate to Commercialize Uterine Fibroid Drug Linzagolix
13/10OBSEVA : Syneos Health to Jointly Commercialize Uterine Fibroids Drug
13/10Obseva meldet Zusammenarbeit mit Syneos Health zur Vermarktung von Linzagolix
13/10ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
13/10ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
12/10ObsEva SA announced that it expects to receive $128.5875 million in funding from JGB Po..
30/09OBSEVA : Names Luigi Marro as Chief Transformation Officer
30/09Obseva ernennt Luigi Marro zum ersten CTO
30/09OBSEVA : Names Chief Transformation Officer
30/09OBSEVA : Announces Appointment of Luigi Marro as Chief Transformation Officer
30/09ObsEva SA Announces Appointment of Luigi Marro as Chief Transformation Officer and Memb..
15/09OBSEVA : Seeks US FDA Nod for Uterine Fibroids Drug; Shares Up 5%
15/09OBSEVA : Submits New Drug Application to FDA for Uterine Fibroids Drug Linzagolix
15/09Obseva stellt US-Zulassungsantrag für Medikament zur Behandlung von Uterusmyomen
15/09OBSEVA : Announces Submission of New Drug Application to U.S. FDA for Linzagolix for the T..
15/09ObsEva Announces Submission of New Drug Application to U.S. FDA for Linzagolix for the ..
07/09OBSEVA : to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
05/08OBSEVA : INDEX TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Form 6-K)
05/08OBSEVA : Q2 Half Year Report 2021
05/08OBSEVA : Q2 Loss Narrows, Operating Expenses Rise
05/08OBSEVA : H1 Loss Narrows on Lower Expenses
05/08Obseva dämmt Verlust im Q2 leicht ein
05/08ObsEva Announces Second Quarter 2021 Financial Results and Business Update
05/08Obseva Sa Reports Earnings Results for the Second Quarter Ended June 30, 2021
04/08OBSEVA : In Vitro Fertilization Therapy Improves Live Birth Outcomes In Trials
04/08OBSEVA : Announces Two Cornerstone Publications Describing Clinical Trials of Nolasiban fo..
04/08ObsEva Announces Two Cornerstone Publications Describing Clinical Trials of Nolasiban f..
03/08OBSEVA : to Present at Upcoming Investor Conferences
27/07ObsEva Shares Climb 10% on Licensing Deal With Organon
27/07SECTOR UPDATE : Health Care Stocks Mixed Premarket Tuesday
27/07OBSEVA : Organon and ObsEva Enter Global License Agreement to Develop and Commercialize Eb..
27/07ObsEva Shares Buoyed After License Agreement With Organon
27/07OBSEVA : Grants Organon Global License to Develop, Commercialize Preterm Labor Treatment C..
27/07Obseva schliesst mit Organon Lizenzabkommen für Ebopiprant (OBE022)
27/07OBSEVA : Grants Organon Global License To Develop, Commercialize Preterm Labor Treatment
27/07OBSEVA : Organon and ObsEva Enter Global License Agreement to Develop and Commercialize Eb..
27/07Organon and ObsEva Enter Global License Agreement to Develop and Commercialize Ebopipra..
02/07ObsEva to Present Ebopiprant (OBE022) Data at the Society for Reproductive Investigatio..
30/06OBSEVA : Says Yselty Shows Potential Against Uterine Disease in Open-Label Pilot Study
30/06Obseva stellt Daten aus verschiedenen Studien mit Yselty an Fachkongress vor
1  2  3  4  5  6  7Suiv.